U.S., July 17 -- ClinicalTrials.gov registry received information related to the study (NCT07709624) titled 'Evaluating the Treatment Outcomes of Tafasitamab in Patients With Relapsed/ Refractory Diffuse Large B-cell Lymphoma: a Real-world Evidence Study' on July 07.
Brief Summary: To evaluate the efficacy of tafasitamab in patients with relapsed/ refractory diffuse large B-cell lymphoma
*To evaluate best objective response rate (ORR)
Study Start Date: Dec. 01, 2025
Study Type: OBSERVATIONAL
Condition:
DLBCL
Intervention:
DRUG: Minjuvi
Observation study, collect data only
Recruitment Status: ACTIVE_NOT_RECRUITING
Sponsor: TTY Biopharm
Published by HT Digital Content Services with permission from Health Daily Digest....